Skip to main content
Clinical Trials/NCT03285165
NCT03285165
Suspended
Phase 2

Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients With and Without Traumatic Brain Injury.

Assiut University1 site in 1 country60 target enrollmentStarted: September 14, 2017Last updated:

Overview

Phase
Phase 2
Status
Suspended
Enrollment
60
Locations
1
Primary Endpoint
Middle cerebral artery flow velocity

Overview

Brief Summary

Serial transcranial Doppler (TCD) exams in healthy volunteers and in animal models showed a strong linear relationship between middle cerebral artery (MCA) flow velocity (FV) and dexmedetomidine infusion. The concomitant elevation of pulsatility index (PI) indicates vasoconstriction of the cerebral vasculature as the most profound underlying mechanism.

Detailed Description

Available clinical evidence on the use of dexmedetomidine sedation in neurosurgical and neurocritical care is limited and no definite conclusion can be drawn. There is a need for The use of dexmedetomidine might be a useful adjunct in clinical situations when the increase in CBF could be detrimental such as vasogenic cerebral edema (i.e., TBI, large brain tumors). However, dexmedetomidine sedation is questionable in patients with subarachnoid hemorrhage and acute stroke, since the associate drop in arterial pressure could worsen the coexisting increase in circulating catecholamines and massive sympathetic outflow. Further high-quality RCTs to evaluate the use of dexmedetomidine as a sedative agent both in general ICU patients and in patients with TBI.

Transcranial Doppler (TCD) is a simple noninvasive bedside tool to assess the cerebral blood flow pattern. The new development of transcranial color Doppler with angle correction option helps to improve the sensitivity of test results. TCD can assess the evolution of CBF alterations and possibly cerebral autoregulation performance and ICP estimation in patients presenting with cerebral pathology.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Masking Description

double-blind

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult trauma patients (18-50 years old, ASA I-II).
  • With and without mild TBI.
  • Mild traumatic brain injury will include; brain edema, brain contusion, fracture base, fissure fracture and depressed fracture.
  • The severity of traumatic brain injury will be defined as mild based on basal Glasgow Coma Scale and basal Computerized tomography scanning.
  • Requirements of endotracheal intubation, mechanical ventilation and light to moderate sedation because of associated abdominal or chest traumatic injuries.
  • The sedation needed should of an estimated duration not less than 24h.
  • Baseline hemodynamic parameters within the normal range.
  • Baseline middle cerebral artery flow velocity within the normal range.

Exclusion Criteria

  • Severe traumatic brain injury, subarachnoid hemorrhage and Intra-cerebral hemorrhage.
  • Spinal cord injury.
  • Hemodynamically unstable patients and patients on inotropes.
  • Patients who have a cardiac pacemaker or automatic implantable cardioverter defibrillator.
  • Patients with hepatic or renal impairment.
  • Pregnant females.
  • Patients who are incarcerated.

Arms & Interventions

DEX I

Active Comparator

Trauma Patients without TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.

Intervention: 0.2-0.7 mcg/kg/h dexmedetomedine infusion. (Drug)

DEX II

Active Comparator

Trauma Patients with TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.

Intervention: 0.2-0.7 mcg/kg/h dexmedetomedine infusion. (Drug)

Propofol I

Active Comparator

Trauma Patients without TBI received 10-70 mcg/kg/h propofol infusion.

Intervention: 10-70 mcg/kg/h propofol infusion. (Drug)

Propofol II

Active Comparator

Trauma Patients with TBI received 10-70 mcg/kg/h propofol infusion.

Intervention: 10-70 mcg/kg/h propofol infusion. (Drug)

Outcomes

Primary Outcomes

Middle cerebral artery flow velocity

Time Frame: 24 hours

1. Right and left middle cerebral artery (MCA) will be measured via trans-temporal window and the depth of insinuation will be between 30-60 mm with the subject's head in neutral position. Mean values of simultaneously measured invasive blood pressure recordings and the outer envelope of time averaged MCA flow velocity (FV) recordings during ten consecutive cardiac cycles

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Hala Saad Abdel-Ghaffar

Assisstant professor in anesthesia and intensive care, Faculty of medicine, Assiut university, Egypt.

Assiut University

Study Sites (1)

Loading locations...

Similar Trials